SavedAdd your journal

Journals / Turkish Journal of Hematology / 2012 / Cilt: 29 - Sayı: 3

Philadelphia negatif kronik miyeloproliferatif neoplazili hastaların tanısında JAK2V617F mutasyonu ile kemik iliğindeki fibrozun ilişkisi

The association between JAK2V617F mutation and bone marrow fibrosis at diagnosis in patients with Philadelphia-negative chronic myeloproliferative neoplasms

M. Cem AR
Deram BÜYÜKTAŞ
A. Emre EŞKAZAN
ŞENİZ ÖNGÖREN AYDIN
Eda TANRIKULU
zafer BAŞLAR
A. Nur BUYRU
AHMET BURHAN FERHANOĞLU
Yıldız AYDIN
Nükhet TÜZÜNER
Teoman SOYSAL
Pages
242–247
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Molecular mechanisms or genetic defects other than JAK2V617F may underlie the occurrence of bone marrow fibrosis in patients with MPNs.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Bone marrow fibrosis is the second most common complication that causes morbidity and mortality in patients with Philadelphia-negative myeloproliferative neoplasms (MPNs).
📊
Key Findings & Data:The aim of this study was to investigate the association between JAK2V617F mutation and bone marrow fibrosis at diagnosis in patients with MPNs.
💡
Conclusion & Impact:Conclusion: Molecular mechanisms or genetic defects other than JAK2V617F may underlie the occurrence of bone marrow fibrosis in patients with MPNs.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Bone marrow fibrosis is the second most common complication that causes morbidity and mortality in patients with Philadelphia-negative myeloproliferative neoplasms (MPNs). The aim of this study was to investigate the association between JAK2V617F mutation and bone marrow fibrosis at diagnosis in patients with MPNs. Material and Methods: In total, 149 patients with MPNs were retrospectively evaluated to determine if there was an association between the histological grade of bone marrow fibrosis and JAK2V617F mutation. Results: In all, 67.7% of the patients carried the mutated JAK2 gene. The presence of JAK2V617F mutation was not associated with the occurrence of bone marrow fibrosis (P = 0.55) or its grade at diagnosis (P = 0.65). Conclusion: Molecular mechanisms or genetic defects other than JAK2V617F may underlie the occurrence of bone marrow fibrosis in patients with MPNs.

Özet

Amaç: Kemik iliği fibrozu, Philadelphia negatif miyeloproliferatif neoplazili (MPN) hastalarda morbidite ve mortaliteye yol açan ikinci en sık komplikasyondur. Bu çalışmanın amacı MPN’li hastalarda tanı anında kemik iliğinde görülen fibroz ile JAK2V617F mutasyonu arasındaki ilişkinin araştırılmasıdır. Gereç ve Yöntemler: Çalışmaya retrospektif olarak dahil edilen 149 MPN tanılı hasta JAK2V617F mutasyonu ile kemik iliğindeki fibroz arasındaki ilişki açısından değerlendirilmiştir. Bulgular: Çalışmaya alınan hastaların %67.7’sinde JAK2V617F gen mutasyonuna rastlandı. Ancak JAK2V617Fmutasyonu ile kemik iliğindeki fibroz varlığı ve derecesi arasında ilişki saptanmadı (sırasıyla, P = 0.55 ve P = 0.65). Sonuç: MPN’de görülen kemik iliği fibrozunun altında JAK2V617F mutasyonu dışında bazı moleküler mekanizma veya genetik bozuklukların yattığı sonucuna varılmıştır.

🔖

Cite This Article

AR, M. C., BÜYÜKTAŞ, D., EŞKAZAN, A. E., AYDIN, Ş. Ö., TANRIKULU, E., BAŞLAR, Z., BUYRU, A. N., FERHANOĞLU, A. B., AYDIN, Y., TÜZÜNER, N., SOYSAL, T. (2012). Philadelphia negatif kronik miyeloproliferatif neoplazili hastaların tanısında JAK2V617F mutasyonu ile kemik iliğindeki fibrozun ilişkisi. Turkish Journal of Hematology, Cilt: 29 - Sayı: 3, 242–247. https://ajindex.com/articles/412631

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA, Barosi G, Vestovsek S, Birgegard G, Mesa R, Reilly JT, Gisslinger H, Vannucchi AM, Cervantes F, Finazzi G, Hoffman R, Gilliland DG, Bloomfield CD, Vardiman JW. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis: Recommendations from an ad hoc international expert panel. Blood 2007
  2. 110 (4): 1092-1097 2. James C, Ugo V, Le Couédic JP, Staerk J, Delhommeau F, Lacout C, Garçon L, Raslova H, Berger R, Bennaceur- Griscelli A, Villeval JL, Constantinescu SN, Casadevall N, Vainchenker W. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005
  3. 1148 3. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC. A gain-of- function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005
  4. 1790 4. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, Scott MA, Erber WN, Green AR. Cancer Genome Project: Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005
  5. 1061 5. Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med 2000
  6. 1265 6. Cervantes F, Passamonti F, Barosi G. Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders. Leukemia 2008
  7. 914 7. Tefferi A, Lasho TL, Schwager SM, Steensma DP, Mesa RA, Li CY, Wadleigh M, Gary Gilliland D. The JAK2V617F tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: Lineage specificity and clinical correlates. Br J Haematol 2005
  8. 328 8. Tefferi A, Lasho TL, Schwager SM, Strand JS, Elliott M, Mesa R, Wadleigh M, Lee SJ, Gilliland DG. The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera. Cancer 2006
  9. 106 (3): 631-635 9. Passamonti F, Rumi E, Pietra D, Della Porta MG, Boveri E, Pascutto C, Vanelli L, Arcaini L, Burcheri S, Malcovati L, Lazzarino M, Cazzola M. Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. Blood 2006
  10. 3682 10. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Eds. Steven H. Swerdlow, Elias Campo, Nancy Lee Haris, Elaine S. Jaffe,